to precision medicine

Transcription

1 QIAGEN at the AMP 2018 Annual Meeting yourpath Discover to precision medicine Sample to Insight

2 Discover your path to precision medicine Lead the way with QIAGEN, from Sample to Insight Every day, data and technologies reveal new molecular insights into disease, giving us more possibilities for guiding treatment decisions and improving healthcare. Join us at AMP to share how you are harnessing the power of genomics and clinical molecular testing technologies. Whether you re using PCR or NGS, targeted panels or whole-genome sequencing, mono- or multiplex testing, QIAGEN empowers you on your path. From Sample to Insight, QIAGEN supports your journey to precision medicine. 2 AMP 2018

3 Contents GeneReader: A complete end-to-end NGS solution for clinical cancer research Dr. Sergio Marchini, Dr. Suman Verma, Prof. Dr. Peter J. Wild Improving syndromic respiratory testing with QIAGEN s DiagCORE system Dr. Steve Young, Dr. Gorm Lisby Identification of inherited genetic risk factors of pancreatic cancer using a targeted sequencing approach in a large cohort Dr. Fergus Couch Better Knowledge, Better Care: Precision medicine for any cancer, any assay, on your platform Dr. Dan Richards AMP

4 GeneReader: A complete end-to-end NGS solution for clinical cancer research Dr. Sergio Marchini, PhD, Head, Translational Genomic Unit, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano, Italy Dr. Suman Verma, VP of Genomics Services, ResearchDx, California, USA Prof. Dr. Peter J. Wild, Director of the Senckenberg Institute for Pathology, University Hospital Frankfurt, Germany Recent years have seen revolutionary advances in our collective understanding of the genetic basis of cancer. Many of these developments, especially in the field of prognostic and diagnostic biomarker discovery have been made possible by technologies like next generation sequencing. With these insights driving development of groundbreaking targeted therapies, there has never been a more exciting or important time to be a researcher in translational oncology research. Each of our 3 speakers at AMP is at the forefront in this field and will be sharing their latest discoveries and experiences with NGS in the oncology space. Find out how you can implement NGS in your lab within 30 days in booth #607! Dr. Sergio Marchini will present data on BRCA 1/2 generated on a sample to insight NGS solution, Dr. Suman Verma will speak about verification of the GeneReader NGS System workflow with a comprehensive lung cancer panel, while Prof. Peter Wild will present data from the German Genomic Medicine Network, generated using a customized QIAact targeted panel. Corporate Workshop Day! Date: Oct 31, 2018 Time: 2:00 2:50 pm CDT Place: Room 221 A and B 4 AMP 2018

5 Improving syndromic respiratory testing with QIAGEN s DiagCORE system Steve Young, PhD, Director of Research and Clinical Trials at TriCore Reference Laboratories, Albuquerque, New Mexico Jan Gorm Lisby, MD, PhD, Section Chief, Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen, Denmark Acute respiratory tract infections are caused by a wide range of viral and bacterial pathogens, and may share similar clinical presentations. Syndromic testing with multiplex molecular panels offers clinical labs a way to quickly distinguish between a broad array of respiratory pathogens. Join Dr. Steve Young at our corporate workshop and Dr. Gorm Lisby at our Innovation Spotlight Stage where they will present a new technology for multiplexed respiratory testing in acutely ill patients. They will be sharing data demonstrating the capabilities of the DiagCORE system for syndromic respiratory testing. Dr. Young and Dr. Lisby will also be sharing their impressions on the ease of doing comprehensive syndromic testing using the QIAGEN solution. The QIAstat-Dx is coming soon Experience the next generation of syndromic insights in booth #607! Corporate Workshop Day! Date: Oct 31, 2018 Time: 3:00 3:50 pm CDT Place: Room 221 A and B the Innovation Spotlight Stage! Date: Nov 2, 2018 Time: 12:00 12:30 pm CDT Place: On the show floor AMP

6 Identification of inherited genetic risk factors of pancreatic cancer using a targeted sequencing approach in a large cohort Fergus Couch, PhD, Mayo Clinic, USA Pancreatic cancer has one of the worst survival outcomes for any type of cancer. Given the high fatality rates, identifying individuals at risk by testing for inherited susceptibility is crucial for improving outcomes. Join us in this workshop to hear Dr. Fergus Couch from the Mayo Clinic discussing his lab s study where 21 cancer predisposition genes were sequenced using a QIAseq targeted DNA panel to determine which ones were associated with an increased risk for pancreatic cancer. The study consisted of 3,030 cases and 123,136 controls and discovered genes independently associated with disease. Dr. Couch will present the results of this study and outline methodologies to overcome challenges associated with targeted sequencing in large studies. Talk with our experts about your sequencing challenges in booth #607! Corporate Workshop Day! Date: Oct 31, 2018 Time: 4:00 4:50 pm CDT Place: Room 221 A and B 6 AMP 2018

7 Better Knowledge, Better Care: Precision medicine for any cancer, any assay, on your platform Dan Richards, PhD, QIAGEN Whether cost, complexity or capacity, today s clinical labs face significant roadblocks in delivering precision medicine insights to pathologist communities and their patients. QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, Dan Richards, Vice President of Biomedical Informatics at QIAGEN and co-founder of Ingenuity Systems, will present a lung cancer case study to show how QIAGEN Clinical Insight (QCI ), our flexible clinical decision support suite, automates, accelerates and advances the interpretation and reporting of genetic variants. Compatible with any NGS platform, running any assay, targeting somatic, hereditary, hematological or childhood cancers, QCI Interpret classifies variants according to professional guidelines using multiple lines and levels of evidence that you can easily review. When coupled with QCI Analyze Universal, our new push-button software for the secondary analysis of NGS data, QCI Interpret makes it easier and in many cases feasible to deploy an end-to-end workflow to extract clinically actionable information from cancer tests data. Demo QCI Interpret to explore evidence-based reporting for any cancer, any assay, on your platform in booth #607! the Innovation Spotlight Stage! Date: Nov 1, 2018 Time: 12:00 12:30 pm CDT Place: On the show floor AMP

8 QIAGEN Inc Germantown Road Germantown MD USA Join us at the AMP 2018 in San Antonio Nov 1 3 We re looking forward to seeing you there! Find out more: AMP.qiagen.com Follow us on Find out about our Corporate Workshop and Innovation Spotlight Stage highlights Experience our Sample to Insight Solutions in booth #607 Trademarks: Sample to Insight, QIAstat-Dx, QCI (QIAGEN Group); GeneReader (Intelligent Bio-Systems, Inc.). PROM / QIAGEN, all rights reserved.